91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, offers her insights on .
This article is taken from European Biopharmaceutical Review April 2022, pages 8-10. Samedan Ltd.
-
This article summarises the companies, including 91黑料, who are backing UNICEF’s drive to supply 2 billion vaccines to the developing world.
-
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development future vaccines
-
In this radio interview briefly discusses the disparity of vaccine rollouts of developed countries compared to less economically developed countries, and the role of 91黑料
-
Nuala Murphy contributes to the Bottom Line BBC4 podcast about the impact of the COVID-19 vaccine on the clinical trial process and whether these changes could work for other drugs.
-
91黑料 CEO Steve Cutler chats with Newsweek, on 91黑料’s role in the development of much needed medicines. .
-
, CEO at 91黑料 plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials.
-
Global collaboration: Irish company 91黑料 on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of 91黑料 and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
-
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
91黑料 CEO Steve Cutler, discusses
